Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Down 31.1% in February

Revelation Biosciences, Inc. (NASDAQ:REVB) saw a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 61,700 shares, a decrease of 31.1% from the February 13th total of 89,500 shares. Based on an average daily volume of 214,800 shares, the short-interest ratio is presently 0.3 days. Approximately 6.8% of the shares of the company are sold short.

Revelation Biosciences Stock Down 11.8 %

Shares of Revelation Biosciences stock opened at $3.00 on Tuesday. The company has a market cap of $804,000.00, a price-to-earnings ratio of -0.01 and a beta of 0.17. The company’s 50 day moving average is $4.80 and its 200 day moving average is $9.30. Revelation Biosciences has a twelve month low of $2.36 and a twelve month high of $60.80.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.